A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

To join this study, you need to be at least 18 years old and have a confirmed long-term Hepatitis B infection for at least six months. You must also be taking your current Hepatitis B medication (like tenofovir or entecavir) regularly and stably for at least six months, with no plans to change it during the study. Your current medication should be successfully controlling the virus to a very low level in your blood.

There are also some things that would mean you can't join. For example, if you have other serious health problems, such as moderate to severe other liver diseases, recent heart problems, uncontrolled diabetes, or certain other infections (like Hepatitis C, HIV, or Hepatitis D). You also can't have a history or suspicion of liver scarring (cirrhosis) or liver cancer.

It's important that you would be willing and able to stop your current Hepatitis B medication later in the study if the doctors think it's appropriate for your care within the study's plan. Both men and women are welcome to participate.

If you decide to take part, you will continue your current Hepatitis B medication as usual in the beginning. The study involves taking two different new medications, DAP/TOM and then bepirovirsen, over a period of time. You will be assigned to receive one of two different doses of DAP/TOM. You might also receive a placebo, which looks like the active drug but contains no medicine, to help researchers understand the true effect of the study drugs.

Throughout the study, you'll have regular visits to the clinic for medical check-ups, blood tests, and perhaps other assessments. These tests help doctors monitor your health, how the medicines are working, and check for any side effects. The total duration of your involvement in the study will be agreed upon with the study team, and it involves a follow-up period after you stop taking the study medications.